PTC Therapeutics Inc (NAS:PTCT)
$ 36.53 3.23 (9.7%) Market Cap: 2.80 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

PTC Therapeutics Inc at Jefferies Gene Therapy Summit Transcript

Oct 08, 2019 / 04:35PM GMT
Release Date Price: $33.65 (-1.03%)
Unidentified Participant

Thanks, everyone, for attending the Jefferies Gene Therapy Summit this afternoon. I'd like to welcome our next company. We have PTC Therapeutics. And I'd like to introduce Jodi Cook, nearest to me, Head of the Gene Therapy and Strategy group, and formerly from Agilis. And then Nikolai Naryshkin, the Vice President of External Research and Alliance Management.

So given this is a gene therapy summit, Jodi, maybe we can start with the Company's AADC deficiency gene therapy program. Can you just maybe go over the clinical data to date? I think you presented and reported on data up to 26 patients. So maybe you can provide that for the audience, and then we'll go into some of the details.

Jodi Cook
PTC Therapeutics, Inc. - Head of Gene Therapy Strategy

Sure. Thank you very much for having us. Let me tell you a little bit about our AADC program. It's -- AADC is a rare genetic disease where patients are born with the inability actually to make dopamine, so they really have no volitional -- they don't develop volitional motor movement.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot